ADXS 31164 - Advaxis

Drug Profile

ADXS 31164 - Advaxis

Alternative Names: ADXS-cHER2; ADXS-HER2; ADXS-HER2 construct vaccine; ADXS31-164; Lovaxin B

Latest Information Update: 14 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Pennsylvania
  • Developer Advaxis; University of Pennsylvania
  • Class Cancer vaccines
  • Mechanism of Action ERBB 2 receptor antagonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteosarcoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Osteosarcoma; Solid tumours
  • No development reported Breast cancer

Most Recent Events

  • 13 Sep 2017 ADXS 31164 is available for licensing as of 11 Sep 2017.
  • 11 Sep 2017 Suspended - Phase-I for Solid tumours (Late-stage disease, Metastatic disease) in USA (Parenteral)
  • 11 Sep 2017 Suspended - Preclinical for Osteosarcoma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top